Roivant Sciences (ROIV) | Stock Overview & Key Data
Roivant Sciences Performance Comparison
Stock Range
Today's Range
Low: $11.68
High: $11.91
on August 15, 2025
52 Week Range
Low: $8.73
High: $13.06
on April 7, 2025
on September 9, 2024
All-Time High: $16.76 on December 20, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$8.1B
EPS
-1.09
P/E Ratio (TTM)
1.95
Forward P/E
-9.96
P/B Ratio
1.76
PEG Ratio
-0.01
Div. Yield
N/A
ROE
-3.32%
Beta
1.149
Debt to Equity
1.93
Financial Highlights
Profitability
Gross Margin
92.90%
Operating Margin
-13,130.05%
Profit Margin
96.86%
Returns and Earnings
Return on Assets (TTM)
-3.16%
Return on Equity (TTM)
-3.32%
EBITDA
$-1.1B
Net Income (TTM)
$-774.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.03
Quarterly Revenue Growth (YoY)
-72.80%
Quarterly Earnings Growth (YoY)
-96.06%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences ROIV | 8.09B Mid-cap | 3.13% | 4.31% | 10.13% | 10.96% | -1.90% | 5.90% | 220.27% | 19.46% |
| Vertex VRTX | 100.38B Large-cap | 7.16% | -15.38% | -9.57% | -15.00% | -3.20% | -17.72% | 31.35% | 44.79% |
| Regeneron REGN | 61.52B Large-cap | 3.09% | 5.92% | -0.78% | -14.65% | -18.85% | -50.78% | -6.14% | -4.14% |
| Moderna MRNA | 10.90B Large-cap | 7.27% | -11.27% | 18.48% | -21.62% | -33.29% | -67.73% | -80.82% | -57.83% |
| BridgeBio Pharma BBIO | 9.81B Mid-cap | 10.18% | 9.26% | 52.10% | 44.60% | 81.99% | 110.33% | 394.89% | 82.18% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
Ownership & Short Interest
Insider Ownership
26.39%
Institutional Ownership
77.09%
Shares Short
38M
Short Ratio
6.62
Short % of Shares Outstanding
7.53%
Average 10-Day Volume
5M
Average 90-Day Volume
5M
Roivant Sciences Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Roivant Sciences would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ROIV's 52-week high and low?
- In the last 52 weeks, Roivant Sciences reached a high of $13.06 (on September 9, 2024) and a low of $8.73 (on April 7, 2025).
- What is the market cap and P/E ratio for ROIV?
- Curious about Roivant Sciences's size and valuation? Its market capitalization stands at 8.09B. When it comes to valuation, the P/E ratio (trailing twelve months) is 1.95, and the forward P/E (looking ahead) is -9.96.
- Does ROIV pay dividends? If so, what's the yield?
- As for dividends, Roivant Sciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Roivant Sciences's main competitors or similar companies to consider before investing?
When looking at Roivant Sciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.38B Healthcare Biotechnology -17.72% 31.35% Regeneron
REGN61.52B Healthcare Biotechnology -50.78% -6.14% Moderna
MRNA10.90B Healthcare Biotechnology -67.73% -80.82% BridgeBio Pharma
BBIO9.81B Healthcare Biotechnology 110.33% 394.89% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Roivant Sciences Ltd? (e.g., ROE, Debt/Equity)
- To get a sense of Roivant Sciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -3.32%, the Debt to Equity ratio from the most recent quarter is 1.93, and its Gross Profit Margin stands at 92.90%.
- What is the recent revenue and earnings growth for ROIV?
- Looking at Roivant Sciences's growth, its revenue over the trailing twelve months (TTM) was $23M. Compared to the same quarter last year (YoY), quarterly revenue grew by -72.80%, and quarterly earnings saw a YoY growth of -96.06%.
- How much of ROIV stock is held by insiders and institutions?
- Wondering who owns Roivant Sciences stock? Company insiders (like executives and directors) hold about 26.39% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 77.09%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.